MedinCell: upbeat after positive data
This study was conducted in support of the mdc-TTG program, aimed at preventing infection for weeks or months, with a single injection of a long-acting formulation of ivermectin, based on MedinCell's BEPO technology.
It met its primary efficacy endpoint with a 72% reduction in infections in the daily oral ivermectin group, compared with placebo, with acceptable safety and tolerability, and no unexpected safety signals.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction